Novavax to Present at the 27th Annual Piper Jaffray Healthcare Conference
Get Alerts NVAX Hot Sheet
Join SI Premium – FREE
GAITHERSBURG, Md., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the 27th Annual Piper Jaffray Healthcare Conference.
Conference details are as follows:
Date: Tuesday, December 1, 2015Time: 2:00 p.m. U.S. Eastern TimeLocation: New York Palace Hotel, New York CityLive webcast: http://edge.media-server.com/m/p/ui3ne8dn
The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271Source: Novavax, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TME Pharma Publishes 2023 Financial Results and Provides Operating Update
- UNIBAIL-RODAMCO-WESTFIELD Q1-2024 TRADING UPDATE
- AFFIRM FILMS AND PROVIDENT FILMS REVEAL THE OFFICIAL TRAILER FOR THE NEWEST KENDRICK BROTHERS' THEATRICAL RELEASE: 'THE FORGE'
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Piper Jaffray, DavenportSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!